TLSI TriSalus Life Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TLSI

Price (delayed)

$9.62

Market cap

$257.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.73

Enterprise value

$247.23M

Highlights
TLSI's EPS has soared by 96% YoY and by 92% QoQ
TriSalus Life Sciences's equity has soared by 85% YoY
TriSalus Life Sciences's quick ratio has plunged by 60% from the previous quarter
TriSalus Life Sciences's net income has decreased by 28% QoQ and by 25% YoY
Sector: Healthcare
Industry: Medical Devices
Peers: OMER OMGA

Key stats

What are the main financial stats of TLSI
Market
Shares outstanding
26.76M
Market cap
$257.41M
Enterprise value
$247.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.36
Earnings
Revenue
$18.51M
EBIT
-$59.01M
EBITDA
-$58.31M
Free cash flow
-$51.17M
Per share
EPS
-$6.73
Free cash flow per share
-$5.45
Book value per share
-$0.99
Revenue per share
$1.97
TBVPS
$2.62
Balance sheet
Total assets
$25.73M
Total liabilities
$51.66M
Debt
$1.6M
Equity
-$25.94M
Working capital
$6.18M
Liquidity
Debt to equity
-0.06
Current ratio
1.42
Quick ratio
1.04
Net debt/EBITDA
0.17
Margins
EBITDA margin
-315%
Gross margin
85.9%
Net margin
-318.9%
Operating margin
-294.6%
Efficiency
Return on assets
-246.2%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-534.6%
Return on sales
-318.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TLSI stock price

How has the TriSalus Life Sciences stock price performed over time
Intraday
3%
1 week
2.89%
1 month
-1.84%
1 year
-6.69%
YTD
13.85%
QTD
-1.33%

Financial performance

How have TriSalus Life Sciences's revenue and profit performed over time
Revenue
$18.51M
Gross profit
$15.91M
Operating income
-$54.53M
Net income
-$59.04M
Gross margin
85.9%
Net margin
-318.9%
The gross profit has soared by 57% YoY and by 21% QoQ
The revenue is up by 49% year-on-year and by 16% since the previous quarter
TriSalus Life Sciences's operating income has decreased by 48% YoY and by 4.4% from the previous quarter
TriSalus Life Sciences's net income has decreased by 28% QoQ and by 25% YoY

Growth

What is TriSalus Life Sciences's growth rate over time

Valuation

What is TriSalus Life Sciences stock price valuation
P/E
N/A
P/B
N/A
P/S
4.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.36
TLSI's EPS has soared by 96% YoY and by 92% QoQ
TriSalus Life Sciences's equity has soared by 85% YoY
The revenue is up by 49% year-on-year and by 16% since the previous quarter
TLSI's P/S is 43% below its last 4 quarters average of 8.5

Efficiency

How efficient is TriSalus Life Sciences business performance
TriSalus Life Sciences's ROA has decreased by 23% from the previous quarter
TLSI's ROS is up by 16% YoY but it is down by 11% QoQ

Dividends

What is TLSI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TLSI.

Financial health

How did TriSalus Life Sciences financials performed over time
The company's total assets is 50% lower than its total liabilities
TLSI's current ratio has surged by 168% year-on-year but it has dropped by 54% since the previous quarter
TLSI's total liabilities has soared by 106% QoQ and by 51% YoY
TLSI's debt is 106% greater than its equity
TriSalus Life Sciences's debt to equity has plunged by 130% from the previous quarter
TriSalus Life Sciences's equity has soared by 85% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.